LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Eli Lilly (United States), University of California, Los Angeles, Harvard University, Dana-Farber Cancer Institute, Sahlgrenska University Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Third People's Hospital of Chengdu, Hunan Cancer Hospital, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Southern Medical University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Loxo Oncology
OpenAlex ID: W4401513681